Symbol | Exchange | Currency |
|---|
AffyXell, a stem cell joint venture between Avacta Group PLC (LON:AVCT) and Daewoong Pharmaceutical (KS:069620), has raised additional funding from existing and new investors to...
By Samuel Indyk Investing.com – Avacta Group (LON:AVCT) has announced that the next drug candidate using its proprietary pre|CISION platform has been selected for...
By Samuel Indyk Investing.com – Avacta Group (LON:AVCT) has announced that its AffiDX SARS-CoV-2 antigen lateral flow test has received a CE Mark for use as a consumer self-test in...
Here is a list of companies that were popular on the site in the latest week.British American TobaccoShares in British American Tobacco (LON:BATS) were popular on the site last...
GameStopThe GameStop Corp (NYSE:GME) squeeze was back this week amid hopes that the new stimulus checks will work their way into the stock market. After closing last week at...
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
| Average | 154.95 (+40.86% Upside) |
| High | 154.949 |
| Low | 154.949 |
| Price | 110 |
| No. of Analysts | 1 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 214.30 | 215.10 | 210.40 | +2.00 | +0.94% | 11.62M | London | |||
| 6.00 | 6.00 | 6.00 | 0.00 | 0.00% | 2.68M | London | |||
| 90.85 | 91.65 | 90.55 | -0.20 | -0.22% | 16.16M | London | |||
| 93.06 | 93.45 | 92.52 | +0.39 | +0.42% | 58.55M | London | |||
| 347.00 | 354.80 | 343.00 | +1.80 | +0.52% | 824.21K | London | |||
| 488.35 | 493.05 | 482.35 | +4.80 | +0.99% | 24.95M | London | |||
| 10,954.00 | 11,012.00 | 10,890.00 | +30.0 | +0.28% | 769.74K | London | |||
| 46.31 | 47.35 | 45.80 | +0.37 | +0.81% | 83.88M | London | |||
| 77.70 | 81.00 | 77.60 | +1.90 | +2.51% | 373.67K | London | |||
| 235.00 | 238.80 | 235.00 | -2.60 | -1.09% | 18.33M | London | |||
| 0.0825 | 0.0825 | 0.0825 | 0.00 | 0.00% | 37.05M | London | |||
| 1,725.00 | 1,766.00 | 1,725.00 | -7.50 | -0.43% | 1.91M | London | |||
| 194.70 | 194.70 | 191.95 | +0.05 | +0.03% | 3.13M | London | |||
| 28.30 | 28.40 | 28.30 | -0.10 | -0.35% | 130.19K | London | |||
| 456.60 | 457.00 | 452.90 | +1.50 | +0.33% | 7.94M | London |